Q1 2025 Transmedics Group Inc Earnings Call Transcript

May 8, 2025 / 08:30 PM GMT

Release Date Price: €86.08 (+5.05%)

Transcript 10-Q8-K

Key Points

Positve

TransMedics Group Inc (TMDX) reported a record total revenue of $143.5 million for Q1 2025, representing a 48% year-over-year growth.
The company achieved a significant improvement in gross margins, reaching 61.5%, up from 59% in the previous quarter.
TransMedics Group Inc (TMDX) saw a strong increase in transplant services revenue, up 56% year-over-year, driven by higher utilization of their OCS NOP platform.
The company reported an operating profit of $27.4 million, which is a substantial increase from $8.6 million in Q4 2024.
TransMedics Group Inc (TMDX) raised its full-year 2025 revenue guidance to between $565 million and $585 million, indicating confidence in continued growth.

Negative

The company acknowledged potential variability and seasonality in quarterly performance, which could impact results in upcoming quarters.
There are concerns about the potential impact of geopolitical, macroeconomic, and tariff policies on the business, although currently deemed minimal.
Service gross margins declined by 632 basis points year-over-year, primarily due to the higher proportion of aviation business.
The company faces potential competition in the liver transplant market, with new entrants expected later in the year.
There is uncertainty regarding the precise launch timing of new clinical programs, as it depends on FDA approval and other regulatory processes.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

TMDX.OQ - Transmedics Group Inc
Q1 2025 Transmedics Group Inc Earnings Call
May 08, 2025 / 08:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good afternoon and welcome to Transmetics first quarter 2025 earnings conference call.

At this time, all participants are in a listen-only mode. We will be facilitating a question and answer session towards the end of today's call. As a reminder, this call is being recorded for replay purposes. I would now like to turn the call over to Lane Morgan from the Gilmartin Group and a few for a few introductory comments. Please go ahead.

Operator.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------------------
Earlier today, TransMedage released financial results for the quarter

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.